Company Overview

Development Stage

About the Company

[Summary] 服务药物创新、造福人类社会

昭衍是中国首家通过美国FDA GLP检查,并且是*同时具有国际AAALAC(动物福利)认证、中国CFDA GLP认证、欧盟OECD GLP认证以及韩国MFDS GLP认证资质的专业新药临床前安全性评价机构。所提供的试验报告可同时被美国、中国、澳洲、韩国以及欧盟组织成员国等多个国家的食品药品监管部门认可。

昭衍是中国*早的企业化GLP实验室,历经20多年的发展现有员工600多人,动物房容量巨大,实验室功能齐全,能为客户提供研发项目设计个性化方案、药物筛选、药效学研究、药代动力学研究、安全性评价和临床试验以及注册服务的一条龙外包服务,服务内容覆盖了从药物发现直到新药注册的全过程,另外还可提供农药、医疗器械和食品动物的安全性评价以及用于科学研究的高品质实验动物销售服务。客户遍布中国30多个省市以及欧美和东南亚多个国家。评价过的药物品种包括生物制品、化学药、中药,适应症涉及抗肿瘤、抗病毒、免疫调节、糖尿病、造血疾病和出凝血系统疾病等多方面共1400余个品种,近年来仅向USFDA申报的项目就达130多个。

昭衍在北京经济技术开发区及苏州太仓生物医药产业园区都拥有符合国际标准的动物饲养管理设施和现代化的功能实验室,动物饲养设施可饲养猴、狗、猪、兔子、豚鼠及大小鼠等实验动物,功能试验室满足了临检、分析和生物分析、临床和组织病理、细胞生物、电生理、眼科、吸入药理和毒理等相关指标的检测,技术人员熟练掌握静脉注射、肌肉注射、皮下注射、腹腔注射、口服给药、经皮给药、鼻腔喷雾、玻璃体注射、眼底注射等给药方式及动静脉等多种取血方式。

昭衍美国实验室位于美国旧金山湾区。可以为中国及其它国家客户提供美国FDA新药注册和技术咨询服务。

昭衍秉承“服务药物创新、造福人类社会”的宗旨,必将用丰富的经验和坚持不懈的努力为广大客户提供从新药临床前试验到I-IV期临床试验以及新药注册的全程一站式服务。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

昭衍新药 Financing History (1 rounds)

Manage
IPO上市
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market: 主板
  • Deal: 上交所

昭衍新药 How Fast Is Hiring Growing? (200 open positions)

Manage
Note: How fast is hiring at 北京昭衍新药研究中心股份有限公司 growing? 昭衍新药2026: 376 openings (up 127%), 2025: 166 openings (up 388%), 2024: 34 openings, 2021: 1 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

昭衍新药 Master's Degree Job Demand Analysis

(More)
How fast is master's hiring at 北京昭衍新药研究中心股份有限公司 growing? 昭衍新药Master's recruitment over the years: 2025: 53 openings (up 1225%), 2024: 4 openings.

昭衍新药 Doctoral Degree Job Demand Analysis

(More)
+33%
Growth Rate
2026 vs 2025
  • 2025: Up 1700%
昭衍新药 Doctoral Hiring by Year: 2026 — 6 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at 北京昭衍新药研究中心股份有限公司 growing? 昭衍新药Doctorate recruitment over the years: 2026: 24 openings (up 33%), 2025: 18 openings (up 1700%), 2024: 1 openings.

昭衍新药 R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at 北京昭衍新药研究中心股份有限公司? Based on an analysis of 昭衍新药's job postings over the past year, "生物/制药/化工/环保类" demand: 35%, "医疗卫生/美容保健类": 24%, "其他(研发和技术类)": 18.5%, "科研类": 17.2%, "农林渔类": 6%, "计算机/网络/技术类": 5.6%. For reference only.

昭衍新药 — What Are the Salaries Like? (466 records)

Manage
salary range: 4.5K - 50K, 41.4% of roles pay ¥10-20K
Note: salary statistics are based on 466 salary records from the past year and depend on the job sample. For reference only.
How is the salary at 北京昭衍新药研究中心股份有限公司?昭衍新药41.4% of positions earn 10-20K, Fresh graduate salary: ¥11.9K。经营管理类 average salary ¥23.1K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of 昭衍新药

(More)
Are salaries high at 北京昭衍新药研究中心股份有限公司? We provide: 专题负责人,研究员,分析,拓展,兽医,临床,bd,销售,qa,运维,项目经理,饲养员,商务经理,检验,内控,采购,支持专员,研究助理,维保,药物警戒. Click to view detailed salary analysis by job.

昭衍新药 — Fortune 500? (More)

昭衍新药 honors, qualifications & industry associations

昭衍新药 Related Industry Tags

Job Category

  • 经营管理类
    34.6% of total 34.6%
  • 生物/制药/化工/环保类
    34.4% of total 34.4%
  • 医疗卫生/美容保健类
    24.1% of total 24.1%
  • 其他(研发和技术类)
    17.8% of total 17.8%

Education

  • 硕士
    38.8% of total 38.8%
  • 本科
    34.4% of total 34.4%
  • 大专
    14.5% of total 14.5%
  • 博士
    7.5% of total 7.5%

Experience

  • 不限
    36.1% of total 36.1%
  • 1-3年
    27.4% of total 27.4%
  • 3-5年
    17.6% of total 17.6%
  • 5-10年
    14.7% of total 14.7%
View Detailed Analysis

What does 北京昭衍新药研究中心股份有限公司 require? Who is 昭衍新药 hiring? 昭衍新药 recruitment: 经营管理类占比最多占34.6%,其次是生物/制药/化工/环保类占34.4%. What education can get in at 昭衍新药? 硕士占比最多占38.8%,其次是本科占34.4%. High education required at 昭衍新药? 硕士占38.8%,博士占7.5%. Work experience required at 昭衍新药? 不限占比最多占36.1%,其次是1-3年占27.4%. Where are the job locations at 昭衍新药? 北京占比最多占54.6%,其次是苏州占28.6%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 74,934.822万(元)
Legal Representative: 冯宇霞
Date Established:
Credit Code: 9111030210221806X9
Registered Address: 北京市北京经济技术开发区荣京东街甲5号

Partners & Suppliers

为上海医药提供药物安全性评价及实验模型 Source
合作客户 合同研究组织(CRO)
提供药物非临床安全性评价服务 Source
合作客户 药物安全性评价
提供临床前安全性评价服务,双方签订战略合作协议。 Source
合作客户 临床前CRO
提供药物安全性评价服务 Source
合作客户 临床前CRO
为谷雨春提供临床前药效及毒理研究服务 Source
合作客户 CRO/药物研发服务

People who follow 昭衍新药 also follow

昭衍新药 Competitors (Similar Companies)

医药 药效学研究 生物制品 生物医药
医药 新药研发 CRO 医药CRO
“Promoting human health”
“Accelerating global biologic drug R&D processes, reducing R&D costs, a”
“Adhering to the corporate culture of science and excellence, committed”
“Helping partners successfully develop new drugs, reducing R&D costs an”
“Optical module solutions and service provider”
海运 散货船 船舶管理 货运
“A renowned enterprise in China's liver disease and anti-tumor fields”
“Core Mission: Safeguarding Human Health with Life Sciences”
中间体 生产 原料药 中间体生产
“To develop high-quality biologics that are accessible and affordable f”
“Helping people live healthier and happier lives”
“风塔、叶片装备制造龙头企业”
“Use creativity and technology to drive business and social progress”

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates